Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBC

August 25, 2015
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Tolaney believes the standard of care will remain standard chemotherapy for triple-negative disease. However, she feels it is important to learn which patients could benefit from the additional platinum-based therapy.

A common question is whether or not a patient with aBRCAmutation should receive platinum-based therapy. In previous studies, the pathological complete response rates were high for patients with this mutation, so it may be beneficial for this therapy to be incorporated intoBCRAcarriers in the future.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).